TRM-362
Pain (unspecified acute/chronic inflammatory conditions)
UnknownActive
Key Facts
Indication
Pain (unspecified acute/chronic inflammatory conditions)
Phase
Unknown
Status
Active
Company
About Tremeau Pharmaceuticals
Tremeau Pharmaceuticals is a private, clinical-stage biotech company pioneering a novel approach to the non-opioid pain market by developing improved versions of previously established COX-2 inhibitors. Its lead asset, TRM-201 (rofecoxib), is an investigational therapy seeking to re-enter the market with a modern safety understanding, while TRM-362 is a deuterated version of etoricoxib designed to enhance its metabolic profile. The company aims to address significant unmet needs in pain management by providing effective, non-addictive alternatives to opioids, leveraging existing efficacy data and new intellectual property to de-risk development.
View full company profileTherapeutic Areas
Other Pain (unspecified acute/chronic inflammatory conditions) Drugs
| Drug | Company | Phase |
|---|---|---|
| TRM-201 | Tremeau Pharmaceuticals | Unknown |